Thanks, PB,
Just looked at the article.
TomFoolery, but he's in the ball park and has the right idea. Beginning to reconsider the drug discovery trickle category; if the pie is that small and that many blackbirds are eating. It's good to see some figures thrown about concerning market size. He leaves out the middle and small cap biotech universe, so we know the figure is higher, as some of those are drug discovery customers, too. In fact, if we take that figure derived from the pharmas' R&D budget, and tack it onto the YTD biotech financing figures we've also seen recently, we should have an approximate idea of the size of the trickle market. I suspect, however, that I want to apply a different -- higher -- per centage for R&D spending by biotechs than that of pharmas. Anybody care to guess what that figure is, roughly? I'd guess 15 - 20% of cash raised is spent on trickle by biotechs. Putting the total trickle market somewhere the $6 billion per annum range at the moment. Talk about irresponsible, not even back-of-the-envelope figures! Comments?
Cheers, Tuck |
